Quick Answer
Marker Therapeutics, Inc. reported Operating Income of -$12.89 million for fiscal year 2025.
Marker Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$12.89M | -15.9% |
| 2024 | -$11.12M | +23.7% |
| 2023 | -$14.58M | +26.3% |
| 2022 | -$19.79M | +49.9% |
| 2021 | -$39.48M | -36.7% |
| 2020 | -$28.89M | -28.2% |
| 2019 | -$22.53M | +84.8% |
| 2018 | -$148.17M | -1190.7% |
| 2017 | -$11.48M | -35.2% |
| 2016 | -$8.49M | -37.9% |
| 2015 | -$6.16M | -82.7% |
| 2014 | -$3.37M | -26.5% |
| 2013 | -$2.66M | +19.7% |
| 2011 | -$3.32M | +39.4% |
| 2010 | -$5.47M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.14M | +11.0% | +49.9% |
| June 30, 2025 | -$4.26M | -84.6% | +7.5% |
| March 31, 2025 | -$4.61M | -80.8% | -92.0% |
| September 30, 2024 | -$2.40M | +25.0% | -4.0% |
| June 30, 2024 | -$2.31M | +44.2% | +9.5% |
| March 31, 2024 | -$2.55M | +40.9% | +20.3% |
| September 30, 2023 | -$3.20M | +45.1% | +22.6% |
| June 30, 2023 | -$4.13M | +21.5% | +4.1% |
- Marker Therapeutics, Inc. showed a decrease of -15.9% in Operating Income compared to the prior fiscal year.
- Over the 2010–2025 period, Marker Therapeutics, Inc.’s operating income has declined by 135.6% (from -$5.47 million to -$12.89 million).
- The most recent figure is from Marker Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: